The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Mony J de Leon
Project Title: CSF clearance in Alzheimer Disease
Date: [153]
Request ID: D1805
Aim 1: CSF clearance in Alzheimer�s disease
Aim 2:
Aim 3:
Aim 4:
Investigator: Dr. Judy Pa
Project Title: Is CSF sPDGFRβ, a measure of vascular dysfunction, related to functional connectivity among brain regions associated with Alzheimer�s disease
Date: [153]
Request ID: D1804
Aim 1: Determine if vascular impairment affects functional connectivity using rsfMRI data
Aim 2: use DWI data to determine if vascular impairment affects structural connectivity
Aim 3: determine a time line of events, does vascular impairment affect FC first versus SC
Aim 4: explore the relationship between clinical diagnosis, vascular impairment and functional connectivity
Investigator: Isabelle Bos
Project Title: The relationship between dementia risk factors and AD biomarkers in preclinical AD
Date: [153]
Request ID: D1803
Aim 1: investigate the association between AD biomarkers and common risk factors for dementia in cognitively normal individuals and their influence on cognitive decline.
Aim 2:
Aim 3:
Aim 4:
Investigator: Suzanne Schindler
Project Title: Development of a model for time of amyloid accumulation in Late Onset Alzheimer Disease (LOAD)
Date: [153]
Request ID: D1802
Aim 1: To determine whether the model for change in SUVR as a function of SUVR can be further optimized by incorporating additional covariates (e.g. age, APOE e4 genotype)
Aim 2: To examine how other biomarkers change as a function of amyloid time, including CSF biomarkers, imaging biomarkers (structural brain MRI and tau PET) and cognitive measures.
Aim 3: To create a model for estimated time until dementia onset (EYO) in late onset AD using amyloid time and covariates known to affect risk for dementia, including age, gender, years of education, APOE 4 genotype, race and vascular risk factors.
Aim 4:
Investigator: Lan Tan
Project Title: Genome-wide association study based on A/T/N system identifies new susceptibility loci for Alzheimer�s disease
Date: [153]
Request ID: D1801
Aim 1: We conducted a case-control genome-wide association studies (GWAS) based on �A/T/N� system from 699 participants in Alzheimer�s Disease Neuroimaging Initiative (ADNI) cohort. We want to test our findings in Knight ADRC.
Aim 2:
Aim 3:
Aim 4:
Investigator: John Morris
Project Title: African American and Caucasian racial difference
Date: [153]
Request ID: D1732
Aim 1: If CMB (cerebral microbleeds) scale (severity and distribution) is jointly analyzed as function of age and race, after adjustment of other covariates, was there any significant difference between the two races?
Aim 2: If WMH (white matter hyperintensities) scale is jointly analyzed as function of age and race, after adjustment of other covariates, was there any significant difference between the two races?
Aim 3: If global amyloid burden (MCBP or MCSUVR) is jointly analyzed as function of age and race, after adjustment of other covariates, was there any significant difference between the two races?
Aim 4: Is there any overall significant difference between the two races in healthy volunteers and the stroke patients
Investigator: Makoto Ishii
Project Title: Alterations in leptin signaling and the hypothalamus in Alzheimer’s disease
Date: [153]
Request ID: D1731
Aim 1: To determine in longitudinal studies if baseline levels of plasma leptin and related metabolic molecules are associated with increased risk of developing: 1) cognitive decline (CDR 0 to 0.5), 2) Alzheimer’s disease diagnosis, or 3) positive biomarkers for Alzheimer’s disease
Aim 2: To determine in longitudinal studies if baseline body weight or body mass index are associated with increased risk of developing: 1) cognitive decline (CDR 0 to 0.5), 2) Alzheimer’s disease diagnosis, or 3) positive biomarkers for Alzheimer’s disease
Aim 3: To determine whether alterations in baseline hypothalamic volume are evident in cognitively intact individuals with positive CSF biomarkers for Alzheimer’s disease
Aim 4: To determine in longitudinal studies if baseline hypothalamic volume are associated with increased risk of developing: 1) cognitive decline (CDR 0 to 0.5), 2) Alzheimer’s disease diagnosis, or 3) positive biomarkers for Alzheimer’s diseas
Investigator: Mark McAvoy
Project Title: Exploring global changes in the brain’s lateralized organization
Date: [153]
Request ID: D1730
Aim 1: Examine the effects of age and dementia status on the brain’s global lateralization
Aim 2:
Aim 3:
Aim 4:
Investigator: Mark McAvoy
Project Title: Exploring mean global and local BOLD signals in healthy aging and dementia
Date: [153]
Request ID: D1729
Aim 1: Compare the mean global signal with current biomarkers of disease pathology
Aim 2:
Aim 3:
Aim 4:
Investigator: Yi Su
Project Title: Blood-brain barrier and white matter integrity in aging and dementia
Date: [153]
Request ID: D1728
Aim 1: investigate white matter changes in aging and dementia
Aim 2: investigate blood-brain barrier changes in aging and dementia
Aim 3:
Aim 4: